PL3612519T3 - Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe - Google Patents

Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe

Info

Publication number
PL3612519T3
PL3612519T3 PL18718570T PL18718570T PL3612519T3 PL 3612519 T3 PL3612519 T3 PL 3612519T3 PL 18718570 T PL18718570 T PL 18718570T PL 18718570 T PL18718570 T PL 18718570T PL 3612519 T3 PL3612519 T3 PL 3612519T3
Authority
PL
Poland
Prior art keywords
phenyl
acetylamino
hydroxy
methyl
compounds
Prior art date
Application number
PL18718570T
Other languages
English (en)
Inventor
Marta Maria CIFUENTES-GARCIA
Maria Cristina GARCIA-PAREDES
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3612519T3 publication Critical patent/PL3612519T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
PL18718570T 2017-04-18 2018-04-11 Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe PL3612519T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382207 2017-04-18
EP18718570.7A EP3612519B1 (en) 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
PCT/US2018/027005 WO2018194885A1 (en) 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Publications (1)

Publication Number Publication Date
PL3612519T3 true PL3612519T3 (pl) 2022-05-02

Family

ID=58606227

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18718570T PL3612519T3 (pl) 2017-04-18 2018-04-11 Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe
PL21211015.9T PL4039675T3 (pl) 2017-04-18 2018-04-11 Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21211015.9T PL4039675T3 (pl) 2017-04-18 2018-04-11 Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe

Country Status (30)

Country Link
US (2) US11655214B2 (pl)
EP (2) EP3612519B1 (pl)
JP (2) JP7110232B2 (pl)
KR (2) KR102575246B1 (pl)
CN (2) CN117510405A (pl)
AU (2) AU2018255191B2 (pl)
BR (1) BR112019021867A2 (pl)
CO (1) CO2019012767A2 (pl)
CR (1) CR20190519A (pl)
CY (1) CY1125150T1 (pl)
DK (2) DK4039675T3 (pl)
ES (2) ES2906847T3 (pl)
FI (1) FI4039675T3 (pl)
HR (2) HRP20241188T1 (pl)
HU (2) HUE068023T2 (pl)
IL (2) IL270005B (pl)
LT (2) LT4039675T (pl)
MX (2) MX389724B (pl)
MY (1) MY199442A (pl)
NZ (1) NZ758291A (pl)
PH (1) PH12019502363B1 (pl)
PL (2) PL3612519T3 (pl)
PT (2) PT3612519T (pl)
RS (2) RS65914B1 (pl)
SA (1) SA519410320B1 (pl)
SG (1) SG11201909680UA (pl)
SI (2) SI4039675T1 (pl)
SM (2) SMT202200100T1 (pl)
WO (1) WO2018194885A1 (pl)
ZA (1) ZA201906811B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7110232B2 (ja) * 2017-04-18 2022-08-01 イーライ リリー アンド カンパニー フェニル-2-ヒドロキシ-アセチルアミノ-2-メチル-フェニル化合物
KR102897382B1 (ko) * 2018-03-26 2025-12-08 이칸 스쿨 오브 메디슨 엣 마운트 시나이 미세 잔존 암을 치료하는 방법
US20220348584A1 (en) 2019-08-29 2022-11-03 Hibercell, Inc. Perk inhibiting indolinyl compounds
WO2021041970A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting imidazolopyrazine compounds
AU2020340427A1 (en) * 2019-08-29 2022-03-31 Hibercell, Inc. PERK inhibiting compounds
EP4021908A1 (en) 2019-08-29 2022-07-06 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
WO2021231782A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibitors for treating viral infections
WO2021231788A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
CN113234029B (zh) * 2021-05-25 2022-03-22 白银康寓信生物科技有限公司 一种2-氨基-3,5-二卤代吡嗪的合成方法
WO2024206890A1 (en) * 2023-03-30 2024-10-03 Hibercell, Inc. Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
ATE242245T1 (de) 1997-03-19 2003-06-15 Basf Ag Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス, インク. プロテインキナーゼモジュレーターおよびその使用方法
RS52625B (sr) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
WO2007026920A2 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
US20120014911A1 (en) 2009-01-09 2012-01-19 Serge Fuchs Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor
BR112012024380A2 (pt) 2010-03-25 2015-09-15 Glaxosmithkline Llc compostos químicos
EP2986286A1 (en) 2013-04-15 2016-02-24 Universita' Degli Studi di Bari Galloyl benzamide-based compounds as jnk modulators
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
US9586967B2 (en) 2013-11-08 2017-03-07 Ono Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
EP3116877A1 (en) 2014-03-11 2017-01-18 Glaxosmithkline Intellectual Property (No. 2) Limited Chemical compounds acting as perk inhibitors
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
CA2967125C (en) 2014-11-14 2022-10-25 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
RU2018106483A (ru) * 2015-07-24 2019-08-26 Блюпринт Медсинс Корпорейшн Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr
ES2965081T3 (es) 2016-07-07 2024-04-11 Daewoong Pharmaceutical Co Ltd Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
CN106748989B (zh) 2016-11-14 2020-03-17 西安交通大学 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用
WO2018138358A1 (en) 2017-01-30 2018-08-02 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
JP7110232B2 (ja) 2017-04-18 2022-08-01 イーライ リリー アンド カンパニー フェニル-2-ヒドロキシ-アセチルアミノ-2-メチル-フェニル化合物
CN111936136B (zh) 2017-11-14 2024-07-05 儿童医学中心公司 新咪唑并嘧啶化合物及其用途
EP3492454A1 (en) 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
KR102897382B1 (ko) 2018-03-26 2025-12-08 이칸 스쿨 오브 메디슨 엣 마운트 시나이 미세 잔존 암을 치료하는 방법
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020070053A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses

Also Published As

Publication number Publication date
CN110831927B (zh) 2023-07-14
RU2019136694A3 (pl) 2021-05-19
SI3612519T1 (sl) 2022-04-29
CN117510405A (zh) 2024-02-06
HUE068023T2 (hu) 2024-12-28
KR20230129627A (ko) 2023-09-08
IL270005B (en) 2022-01-01
NZ758291A (en) 2025-11-28
MX2022001310A (es) 2022-03-02
WO2018194885A1 (en) 2018-10-25
AU2018255191B2 (en) 2022-04-21
JP2021517555A (ja) 2021-07-26
EP4039675A1 (en) 2022-08-10
EP3612519B1 (en) 2021-12-01
HUE057745T2 (hu) 2022-06-28
DK4039675T3 (da) 2024-09-02
MX389724B (es) 2025-03-20
RS62933B1 (sr) 2022-03-31
PH12019502363B1 (en) 2023-11-15
ES2906847T3 (es) 2022-04-20
CR20190519A (es) 2020-03-06
EP4039675B1 (en) 2024-06-12
DK3612519T3 (da) 2022-03-07
FI4039675T3 (fi) 2024-09-10
HRP20220263T1 (hr) 2022-04-29
CY1125150T1 (el) 2023-06-09
EP3612519A1 (en) 2020-02-26
US11655214B2 (en) 2023-05-23
PT4039675T (pt) 2024-09-16
CO2019012767A2 (es) 2020-04-01
JP7331212B2 (ja) 2023-08-22
JP2022141835A (ja) 2022-09-29
IL288822B2 (en) 2023-06-01
SI4039675T1 (sl) 2024-10-30
RU2019136694A (ru) 2021-05-18
AU2018255191A1 (en) 2019-11-07
KR20190140966A (ko) 2019-12-20
RS65914B1 (sr) 2024-10-31
AU2022206702A1 (en) 2022-08-11
MY199442A (en) 2023-10-28
ZA201906811B (en) 2021-01-27
CA3060564A1 (en) 2018-10-25
PL4039675T3 (pl) 2025-01-07
HRP20241188T1 (hr) 2024-12-06
MX2019012428A (es) 2022-01-28
US20230373922A1 (en) 2023-11-23
SMT202400357T1 (it) 2024-11-15
CN110831927A (zh) 2020-02-21
SA519410320B1 (ar) 2022-05-08
JP7110232B2 (ja) 2022-08-01
BR112019021867A2 (pt) 2020-05-26
AU2022206702B2 (en) 2024-04-11
LT4039675T (lt) 2024-10-10
LT3612519T (lt) 2022-03-25
SMT202200100T1 (it) 2022-03-21
IL288822A (en) 2022-02-01
SG11201909680UA (en) 2019-11-28
ES2988739T3 (es) 2024-11-21
US20210114985A1 (en) 2021-04-22
PT3612519T (pt) 2022-02-22
KR102575246B1 (ko) 2023-09-06
PH12019502363A1 (en) 2020-12-07

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
EP3578560A4 (en) QUINAZOLINE COMPOUND
CL2018000524S1 (es) Golilla
EP3609871A4 (en) ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
EP3589248A4 (en) CRYOTHERAPIES
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3634404C0 (en) PYRAZOLE-BASED MAGL INHIBITORS
EP3588580A4 (en) SCHOTTKY MOS TRENCH DIODE
DK3351526T3 (da) Diisopentylterephthalat
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
EP3654852A4 (en) TOURNIQUET
EP3634397A4 (en) HETEROCYCLYL POLYMETHINE-BASED IR CHROMOPHORES
DK3568655T3 (da) Rekuperator
DK3571580T3 (da) Load-logical-and-shift-guarded-instruktion
LT3464336T (lt) Junginiai
DK3612237T3 (da) Genterapi
EP3611402A4 (en) SERVO CYLINDER
EP3669219C0 (en) NETWORK SCALE
DK3576686T3 (da) Brokbind
DK3568506T3 (da) Offeranode
DK3672941T3 (da) Pyridylpyridonforbindelser
LT3668879T (lt) Nauji junginiai
DK3672962T3 (da) Morpholinylpyridonforbindelser
EP3585140A4 (en) Splicing tape management system
DK3510051T3 (da) Carboxylalkylchitosan